While CT20p has not yet been tested in clinical trials, we anticipate that cytoprotective pro-tumor effects associated with HSP90 inhibitors would not transpire given that reductions in CCT levels do not induce a heat shock response (17) and cct genes have fewer heat shock elements for binding heat shock transcription factors (HSF1 and HSF2) than comparable HSPs (6). The gene discussed is HSF2; the disease is neoplasm.